- Home
- EMX vs VXRT Comparison
EMX vs VXRT Comparison
Compare EMX & VXRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMX
- VXRT
- Stock Information
- Founded
- EMX N/A
- VXRT N/A
- Country
- EMX Canada
- VXRT United States
- Employees
- EMX N/A
- VXRT N/A
- Industry
- EMX
- VXRT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EMX
- VXRT Health Care
- Exchange
- EMX Nasdaq
- VXRT Nasdaq
- Market Cap
- EMX 202.9M
- VXRT 170.2M
- IPO Year
- EMX N/A
- VXRT N/A
- Fundamental
- Price
- EMX $1.81
- VXRT $0.71
- Analyst Decision
- EMX Strong Buy
- VXRT Buy
- Analyst Count
- EMX 1
- VXRT 1
- Target Price
- EMX $7.00
- VXRT $4.00
- AVG Volume (30 Days)
- EMX 315.4K
- VXRT 1.2M
- Earning Date
- EMX 03-24-2025
- VXRT 03-13-2025
- Dividend Yield
- EMX N/A
- VXRT N/A
- EPS Growth
- EMX N/A
- VXRT N/A
- EPS
- EMX N/A
- VXRT N/A
- Revenue
- EMX $26,818,000.00
- VXRT $16,760,000.00
- Revenue This Year
- EMX N/A
- VXRT $128.77
- Revenue Next Year
- EMX $2.34
- VXRT N/A
- P/E Ratio
- EMX N/A
- VXRT N/A
- Revenue Growth
- EMX 25.53
- VXRT 303.27
- 52 Week Low
- EMX $1.47
- VXRT $0.52
- 52 Week High
- EMX $2.15
- VXRT $1.43
- Technical
- Relative Strength Index (RSI)
- EMX 51.89
- VXRT 48.01
- Support Level
- EMX $1.72
- VXRT $0.68
- Resistance Level
- EMX $1.91
- VXRT $0.78
- Average True Range (ATR)
- EMX 0.06
- VXRT 0.05
- MACD
- EMX -0.00
- VXRT -0.00
- Stochastic Oscillator
- EMX 47.37
- VXRT 48.85
About EMX EMX Royalty Corporation (Canada)
EMX Royalty Corp and its subsidiaries operate as a royalty and prospect generator engaged in exploring for and generating royalties from, metals and minerals properties. The company is a precious, and base metals royalty company. The Company augments royalty generation with royalty acquisitions and strategic investments. EMX's royalty and mineral property portfolio consists of properties in North America, Europe, Turkiye, Latin America, Morocco, and Australia.
About VXRT Vaxart Inc
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.